Trial Profile
A Randomized, Double-blind, Multi-center, Phase II Optimal Dose-finding Study to Determine Safety and Efficacy of Medytoxin in Subjects in Benign Masseteric Hypertrophy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2019
Price :
$35
*
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Hypertrophy
- Focus Therapeutic Use
- Sponsors Medytox
- 25 Mar 2019 Status changed from recruiting to completed.
- 19 Nov 2014 New trial record